Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

Table 3

Survival according to molecular markers for TKI-treated cohort.

	Survival	Log rank 𝑃	TTP	Log rank 𝑃
EGFR
MUT	11.7	.131	8.5	.106
WT	5.1		2.7
HER2
MUT	2.7	.340	1.2	.100
WT	6.5		4.1
EGFR (IHC)
Negative	8.9	.700	1.2	.641
Positive	4.6		3.6
EGFR (FISH)
Negative	4.6	.271	3.1	.185
Positive	11.7		8.5
EGFR combination: (Mutation and/or Gene gain)
Negative	4.6	.125	2.2	.145
Positive	11.6		7.7